Generative-AI based Agents to Revolutionize Medical Diagnosis and Treatment of Cancer

The main goal of this opportunity is to develop interactive Generative AI (GenAI) agents that help clinicians gain a complete, end-to-end view of patient care throughout the cancer clinical pathway. The initiative focuses on improving cancer diagnosis and treatment by integrating and interpreting complex medical imaging and health data, generating reliable synthetic data, and using advanced AI methods like deep learning and graph neural networks. Projects should address pattern recognition, reduce diagnostic errors, and support personalized cancer therapy. Efforts must also ensure that AI tools are transparent and trustworthy, in line with ethical standards. Eligible projects must involve entities from the Member States and Associated Countries of the European Union.

• Development of GenAI-based tools that integrate multidimensional and multimodal data for a specified cancer type.

• Creation of GenAI models for synthetic data generation and medical data augmentation to support training.

• Design of interactive autonomous agents for predictive cancer diagnosis using health records, imaging, and genomics.

• Development of AI systems for personalized cancer treatment selection and forecasting of treatment efficacy.

• Construction of GenAI-based knowledge representation systems to improve model interpretability and clinical trust.

Example Projects:

• A research team from Spain and Germany develops a GenAI tool to integrate MRI and pathology data for personalized lung cancer treatment.
• A consortium of three universities from Italy, France, and Sweden creates a synthetic data generator to improve early diagnosis of breast cancer using multimodal health records.
• A start-up from Belgium partners with a hospital in the Netherlands to build an interpretable AI model for colorectal cancer diagnosis, ensuring transparency and ethical compliance.

• Direct personnel costs (researchers, technicians, project management) essential for R&I work.

• Equipment & consumables required for experiments, prototyping, and device development.

• Subcontracting costs for specialized expertise or services not available within the consortium.

• Travel, workshops & networking expenses for collaboration, dissemination, and participation in portfolio-wide activities.

• Piloting ad‑hoc portfolio activities such as joint events, shared toolkits, or commercialization preparation (up to €50,000 per project).

• Budget for this Call: 120,000,000€
• Number of Grants attributed: 8
• Minimum value per project: 500,000€
• Maximum value per project: 4,000,000€
• Maximum project duration: 48 months

• Applicants can be single legal entities or consortia from EU Member States or Associated Countries.
• Single legal entities must be established in a Member State or Associated Country and cannot be mid-caps or larger companies.
• Consortia of two must include independent legal entities from two different eligible countries.
• Consortia of three or more must include at least three independent legal entities, each from a different country, with at least one based in a Member State.
• Eligible applicants include universities, research organizations, SMEs, start-ups, and individuals.
• Projects must address one of the three specified focus areas.
• Applicants must meet the general and challenge-specific eligibility requirements as outlined in the EIC Work Programme 2025.